All manuscripts
Publications CAR T Cells

Global Manufacturing of CAR T Cell Therapy

Published Journal Molecular Therapy - Methods & Clinical Development

Share
10 pages Global Manufacturing of CAR T Cell Therapy

Overview

This review follows CTL019 out of one academic center and into a multi-site manufacturing network, covering leukapheresis, enrichment, activation, lentiviral transduction, bioreactor expansion and cryopreservation. Sourcing the lentiviral vector from one manufacturer minimized site-to-site variation in a two-site study.

What this paper found

Moving CAR T cell therapy from a single academic center to a global, multi-site manufacturing network depends on tightly controlled processes, a consistent viral vector and early planning for regulatory differences between regions. This review of the CD19 product CTL019 describes the steps from leukapheresis, T cell enrichment and bead or aAPC activation to lentiviral transduction, bioreactor expansion of up to about 5 L, concentration and cryopreservation. Using one lentiviral vector source, made by Oxford BioMedica, minimized site-to-site variation in a two-site study. Lentiviral vector stocks stayed usable for 4 years at minus 80 °C in the authors' experience. Long-term safety follow-up lasts up to 15 years.

Note: This is a narrative review; some transduction data are described as unpublished.

A major challenge with scaling out the production of CAR T cell therapies is the transition from a flexible process at a single academic institution to a highly controlled process that can be implemented across many collection, manufacturing, and treatment sites (Figure 4). — Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir, Molecular Therapy - Methods & Clinical Development

Study details

Authors
Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir
Institution
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA · Oxford BioMedica, Ltd., Oxford, UK · Cell and Gene Therapies Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Journal
Molecular Therapy - Methods & Clinical Development
Year
2016
PMID / PMC
PMID: 28344995 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy

Explore related

Full citation

Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2016;4:92-101.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →